APO Research
Talk to an analyst

APO RESEARCH · REPORT

In Vivo Pharmacology Model

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global In Vivo Pharmacology Model Market Outlook and Growth Opportunities 2026

3 May 2026199 pages

Choose your research edition.

Industry ResearchIn Vivo Pharmacology Model Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal In Vivo Pharmacology Model Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal In Vivo Pharmacology Model Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In Vivo Pharmacology Model Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal In Vivo Pharmacology Model Market Analysis and Forecast 2026-2032249 pages · $4,950 USD

Market perspective

The global In Vivo Pharmacology Model market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the In Vivo Pharmacology Model market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the In Vivo Pharmacology Model market include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt and Sygnature Discovery, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global In Vivo Pharmacology Model market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of In Vivo Pharmacology Model and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents In Vivo Pharmacology Model revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global In Vivo Pharmacology Model market.

In Vivo Pharmacology Model Segment by Company

NuChem Sciences Inc

Eurofins Discovery

Oncodesign Services

Jubilant Biosys

Pharmaron

Melior Discovery

NUVISAN GmbH

Porsolt

Sygnature Discovery

Aurigene Pharmaceutical Services Ltd

Reaction Biology

Addexbio

Paraza Pharma, Inc

Aragen Life Sciences Ltd

Dalriada

Biocytogen

Charles River Laboratories

Pharmacelsu

HitGen Inc

TCG Lifesciences

In Vivo Pharmacology Model Segment by Type

Inflammation Animal Models

Pain and Neuroscience Animal Models

Diabetes and Metabolic Disorders Animal Models

Oncology Animal Models

Others

In Vivo Pharmacology Model Segment by Application

Cardiovascular Diseases

Neurological Diseases

Autoimmune Diseases

Others

In Vivo Pharmacology Model Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global In Vivo Pharmacology Model status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the In Vivo Pharmacology Model key companies, revenue, market share, and recent developments.

3. To split the In Vivo Pharmacology Model breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions In Vivo Pharmacology Model market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify In Vivo Pharmacology Model significant trends, drivers, influence factors in global and regions.

6. To analyze In Vivo Pharmacology Model competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In Vivo Pharmacology Model market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In Vivo Pharmacology Model and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In Vivo Pharmacology Model.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global In Vivo Pharmacology Model industry.

Chapter 3: Detailed analysis of In Vivo Pharmacology Model company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of In Vivo Pharmacology Model in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of In Vivo Pharmacology Model in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. In Vivo Pharmacology Model Industry Trends Table 2. In Vivo Pharmacology Model Industry Drivers Table 3. In Vivo Pharmacology Model Industry Opportunities and Challenges Table 4. In Vivo Pharmacology Model Industry Restraints Table 5. Global In Vivo Pharmacology Model Revenue by Company (US$ Million) & (2021-2026) Table 6. Global In Vivo Pharmacology Model Revenue Share by Company (2021-2026) Table 7. Global In Vivo Pharmacology Model Company Ranking, (2024-2026) & (US$ Million) Table 8. Global In Vivo Pharmacology Model Key Company Manufacturing Base & Headquarters Table 9. Global In Vivo Pharmacology Model Company, Product Type & Application Table 10. Global In Vivo Pharmacology Model Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global In Vivo Pharmacology Model by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Inflammation Animal Models Table 15. Significant Companies of Pain and Neuroscience Animal Models Table 16. Significant Companies of Diabetes and Metabolic Disorders Animal Models Table 17. Significant Companies of Oncology Animal Models Table 18. Significant Companies of Others Table 19. Global In Vivo Pharmacology Model Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global In Vivo Pharmacology Model Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global In Vivo Pharmacology Model Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global In Vivo Pharmacology Model Sales Value Share by Type (2021-2026) Table 23. Global In Vivo Pharmacology Model Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Cardiovascular Diseases Table 25. Significant Companies of Neurological Diseases Table 26. Significant Companies of Autoimmune Diseases Table 27. Significant Companies of Others Table 28. Global In Vivo Pharmacology Model Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global In Vivo Pharmacology Model Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global In Vivo Pharmacology Model Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global In Vivo Pharmacology Model Sales Value Share by Application (2021-2026) Table 32. Global In Vivo Pharmacology Model Sales Value Share by Application (2027-2032) Table 33. Global In Vivo Pharmacology Model Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global In Vivo Pharmacology Model Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global In Vivo Pharmacology Model Sales Value Share by Region (2021-2026) Table 36. Global In Vivo Pharmacology Model Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global In Vivo Pharmacology Model Sales Value Share by Region (2027-2032) Table 38. Global In Vivo Pharmacology Model Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global In Vivo Pharmacology Model Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global In Vivo Pharmacology Model Sales Value Market Share by Country (2021-2026) Table 41. Global In Vivo Pharmacology Model Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global In Vivo Pharmacology Model Sales Value Market Share by Country (2027-2032) Table 43. NuChem Sciences Inc Company Information Table 44. NuChem Sciences Inc Business Overview Table 45. NuChem Sciences Inc In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. NuChem Sciences Inc In Vivo Pharmacology Model Product Portfolio Table 47. NuChem Sciences Inc Recent Development Table 48. Eurofins Discovery Company Information Table 49. Eurofins Discovery Business Overview Table 50. Eurofins Discovery In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Eurofins Discovery In Vivo Pharmacology Model Product Portfolio Table 52. Eurofins Discovery Recent Development Table 53. Oncodesign Services Company Information Table 54. Oncodesign Services Business Overview Table 55. Oncodesign Services In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Oncodesign Services In Vivo Pharmacology Model Product Portfolio Table 57. Oncodesign Services Recent Development Table 58. Jubilant Biosys Company Information Table 59. Jubilant Biosys Business Overview Table 60. Jubilant Biosys In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Jubilant Biosys In Vivo Pharmacology Model Product Portfolio Table 62. Jubilant Biosys Recent Development Table 63. Pharmaron Company Information Table 64. Pharmaron Business Overview Table 65. Pharmaron In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pharmaron In Vivo Pharmacology Model Product Portfolio Table 67. Pharmaron Recent Development Table 68. Melior Discovery Company Information Table 69. Melior Discovery Business Overview Table 70. Melior Discovery In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Melior Discovery In Vivo Pharmacology Model Product Portfolio Table 72. Melior Discovery Recent Development Table 73. NUVISAN GmbH Company Information Table 74. NUVISAN GmbH Business Overview Table 75. NUVISAN GmbH In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. NUVISAN GmbH In Vivo Pharmacology Model Product Portfolio Table 77. NUVISAN GmbH Recent Development Table 78. Porsolt Company Information Table 79. Porsolt Business Overview Table 80. Porsolt In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Porsolt In Vivo Pharmacology Model Product Portfolio Table 82. Porsolt Recent Development Table 83. Sygnature Discovery Company Information Table 84. Sygnature Discovery Business Overview Table 85. Sygnature Discovery In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sygnature Discovery In Vivo Pharmacology Model Product Portfolio Table 87. Sygnature Discovery Recent Development Table 88. Aurigene Pharmaceutical Services Ltd Company Information Table 89. Aurigene Pharmaceutical Services Ltd Business Overview Table 90. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product Portfolio Table 92. Aurigene Pharmaceutical Services Ltd Recent Development Table 93. Reaction Biology Company Information Table 94. Reaction Biology Business Overview Table 95. Reaction Biology In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Reaction Biology In Vivo Pharmacology Model Product Portfolio Table 97. Reaction Biology Recent Development Table 98. Addexbio Company Information Table 99. Addexbio Business Overview Table 100. Addexbio In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Addexbio In Vivo Pharmacology Model Product Portfolio Table 102. Addexbio Recent Development Table 103. Paraza Pharma, Inc Company Information Table 104. Paraza Pharma, Inc Business Overview Table 105. Paraza Pharma, Inc In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Paraza Pharma, Inc In Vivo Pharmacology Model Product Portfolio Table 107. Paraza Pharma, Inc Recent Development Table 108. Aragen Life Sciences Ltd Company Information Table 109. Aragen Life Sciences Ltd Business Overview Table 110. Aragen Life Sciences Ltd In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Aragen Life Sciences Ltd In Vivo Pharmacology Model Product Portfolio Table 112. Aragen Life Sciences Ltd Recent Development Table 113. Dalriada Company Information Table 114. Dalriada Business Overview Table 115. Dalriada In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Dalriada In Vivo Pharmacology Model Product Portfolio Table 117. Dalriada Recent Development Table 118. Biocytogen Company Information Table 119. Biocytogen Business Overview Table 120. Biocytogen In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Biocytogen In Vivo Pharmacology Model Product Portfolio Table 122. Biocytogen Recent Development Table 123. Charles River Laboratories Company Information Table 124. Charles River Laboratories Business Overview Table 125. Charles River Laboratories In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Charles River Laboratories In Vivo Pharmacology Model Product Portfolio Table 127. Charles River Laboratories Recent Development Table 128. Pharmacelsu Company Information Table 129. Pharmacelsu Business Overview Table 130. Pharmacelsu In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Pharmacelsu In Vivo Pharmacology Model Product Portfolio Table 132. Pharmacelsu Recent Development Table 133. HitGen Inc Company Information Table 134. HitGen Inc Business Overview Table 135. HitGen Inc In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. HitGen Inc In Vivo Pharmacology Model Product Portfolio Table 137. HitGen Inc Recent Development Table 138. TCG Lifesciences Company Information Table 139. TCG Lifesciences Business Overview Table 140. TCG Lifesciences In Vivo Pharmacology Model Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. TCG Lifesciences In Vivo Pharmacology Model Product Portfolio Table 142. TCG Lifesciences Recent Development Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. In Vivo Pharmacology Model Product Image Figure 2. Global In Vivo Pharmacology Model Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 4. Global In Vivo Pharmacology Model Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Inflammation Animal Models Image Figure 8. Pain and Neuroscience Animal Models Image Figure 9. Diabetes and Metabolic Disorders Animal Models Image Figure 10. Oncology Animal Models Image Figure 11. Others Image Figure 12. Global In Vivo Pharmacology Model Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global In Vivo Pharmacology Model Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global In Vivo Pharmacology Model Sales Value Share by Type (2021-2032) Figure 15. Cardiovascular Diseases Image Figure 16. Neurological Diseases Image Figure 17. Autoimmune Diseases Image Figure 18. Others Image Figure 19. Global In Vivo Pharmacology Model Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global In Vivo Pharmacology Model Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global In Vivo Pharmacology Model Sales Value Share by Application (2021-2032) Figure 22. Global In Vivo Pharmacology Model Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global In Vivo Pharmacology Model Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America In Vivo Pharmacology Model Sales Value (2021-2032) & (US$ Million) Figure 25. North America In Vivo Pharmacology Model Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe In Vivo Pharmacology Model Sales Value (2021-2032) & (US$ Million) Figure 27. Europe In Vivo Pharmacology Model Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific In Vivo Pharmacology Model Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific In Vivo Pharmacology Model Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America In Vivo Pharmacology Model Sales Value (2021-2032) & (US$ Million) Figure 31. South America In Vivo Pharmacology Model Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa In Vivo Pharmacology Model Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa In Vivo Pharmacology Model Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Inflammation Animal Models
  • Pain and Neuroscience Animal Models
  • Diabetes and Metabolic Disorders Animal Models
  • Oncology Animal Models
  • Others
Applications
  • Cardiovascular Diseases
  • Neurological Diseases
  • Autoimmune Diseases
  • Others
Companies covered
  • NuChem Sciences Inc
  • Eurofins Discovery
  • Oncodesign Services
  • Jubilant Biosys
  • Pharmaron
  • Melior Discovery
  • NUVISAN GmbH
  • Porsolt
  • Sygnature Discovery
  • Aurigene Pharmaceutical Services Ltd
  • Reaction Biology
  • Addexbio
  • Paraza Pharma, Inc
  • Aragen Life Sciences Ltd
  • Dalriada
  • Biocytogen
  • Charles River Laboratories
  • Pharmacelsu
  • HitGen Inc
  • TCG Lifesciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global In Vivo Pharmacology Model Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global In Vivo Pharmacology Model Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 In Vivo Pharmacology Model Market Dynamics
  1. 2.1 In Vivo Pharmacology Model Industry Trends
  2. 2.2 In Vivo Pharmacology Model Industry Drivers
  3. 2.3 In Vivo Pharmacology Model Industry Opportunities and Challenges
  4. 2.4 In Vivo Pharmacology Model Industry Restraints
3 In Vivo Pharmacology Model Market by Company
  1. 3.1 Global In Vivo Pharmacology Model Company Revenue Ranking in 2025
  2. 3.2 Global In Vivo Pharmacology Model Revenue by Company (2021-2026)
  3. 3.3 Global In Vivo Pharmacology Model Company Ranking (2024-2026)
  4. 3.4 Global In Vivo Pharmacology Model Company Manufacturing Base and Headquarters
  5. 3.5 Global In Vivo Pharmacology Model Company Product Type and Application
  6. 3.6 Global In Vivo Pharmacology Model Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global In Vivo Pharmacology Model Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 In Vivo Pharmacology Model Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 In Vivo Pharmacology Model Market by Type
  1. 4.1 In Vivo Pharmacology Model Type Introduction
  2. 4.1.1 Inflammation Animal Models
  3. 4.1.2 Pain and Neuroscience Animal Models
  4. 4.1.3 Diabetes and Metabolic Disorders Animal Models
  5. 4.1.4 Oncology Animal Models
  6. 4.1.5 Others
  7. 4.2 Global In Vivo Pharmacology Model Sales Value by Type
  8. 4.2.1 Global In Vivo Pharmacology Model Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global In Vivo Pharmacology Model Sales Value by Type (2021-2032)
  10. 4.2.3 Global In Vivo Pharmacology Model Sales Value Share by Type (2021-2032)
5 In Vivo Pharmacology Model Market by Application
  1. 5.1 In Vivo Pharmacology Model Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Neurological Diseases
  4. 5.1.3 Autoimmune Diseases
  5. 5.1.4 Others
  6. 5.2 Global In Vivo Pharmacology Model Sales Value by Application
  7. 5.2.1 Global In Vivo Pharmacology Model Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global In Vivo Pharmacology Model Sales Value by Application (2021-2032)
  9. 5.2.3 Global In Vivo Pharmacology Model Sales Value Share by Application (2021-2032)
6 In Vivo Pharmacology Model Regional Value Analysis
  1. 6.1 Global In Vivo Pharmacology Model Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global In Vivo Pharmacology Model Sales Value by Region (2021-2032)
  3. 6.2.1 Global In Vivo Pharmacology Model Sales Value by Region: 2021-2026
  4. 6.2.2 Global In Vivo Pharmacology Model Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America In Vivo Pharmacology Model Sales Value (2021-2032)
  7. 6.3.2 North America In Vivo Pharmacology Model Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe In Vivo Pharmacology Model Sales Value (2021-2032)
  10. 6.4.2 Europe In Vivo Pharmacology Model Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific In Vivo Pharmacology Model Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific In Vivo Pharmacology Model Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America In Vivo Pharmacology Model Sales Value (2021-2032)
  16. 6.6.2 South America In Vivo Pharmacology Model Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa In Vivo Pharmacology Model Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa In Vivo Pharmacology Model Sales Value Share by Country, 2025 VS 2032
7 In Vivo Pharmacology Model Country-level Value Analysis
  1. 7.1 Global In Vivo Pharmacology Model Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global In Vivo Pharmacology Model Sales Value by Country (2021-2032)
  3. 7.2.1 Global In Vivo Pharmacology Model Sales Value by Country (2021-2026)
  4. 7.2.2 Global In Vivo Pharmacology Model Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt In Vivo Pharmacology Model Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt In Vivo Pharmacology Model Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt In Vivo Pharmacology Model Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 NuChem Sciences Inc
  2. 8.1.1 NuChem Sciences Inc Company Information
  3. 8.1.2 NuChem Sciences Inc Business Overview
  4. 8.1.3 NuChem Sciences Inc In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  5. 8.1.4 NuChem Sciences Inc In Vivo Pharmacology Model Product Portfolio
  6. 8.1.5 NuChem Sciences Inc Recent Developments
  7. 8.2 Eurofins Discovery
  8. 8.2.1 Eurofins Discovery Company Information
  9. 8.2.2 Eurofins Discovery Business Overview
  10. 8.2.3 Eurofins Discovery In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eurofins Discovery In Vivo Pharmacology Model Product Portfolio
  12. 8.2.5 Eurofins Discovery Recent Developments
  13. 8.3 Oncodesign Services
  14. 8.3.1 Oncodesign Services Company Information
  15. 8.3.2 Oncodesign Services Business Overview
  16. 8.3.3 Oncodesign Services In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Oncodesign Services In Vivo Pharmacology Model Product Portfolio
  18. 8.3.5 Oncodesign Services Recent Developments
  19. 8.4 Jubilant Biosys
  20. 8.4.1 Jubilant Biosys Company Information
  21. 8.4.2 Jubilant Biosys Business Overview
  22. 8.4.3 Jubilant Biosys In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jubilant Biosys In Vivo Pharmacology Model Product Portfolio
  24. 8.4.5 Jubilant Biosys Recent Developments
  25. 8.5 Pharmaron
  26. 8.5.1 Pharmaron Company Information
  27. 8.5.2 Pharmaron Business Overview
  28. 8.5.3 Pharmaron In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharmaron In Vivo Pharmacology Model Product Portfolio
  30. 8.5.5 Pharmaron Recent Developments
  31. 8.6 Melior Discovery
  32. 8.6.1 Melior Discovery Company Information
  33. 8.6.2 Melior Discovery Business Overview
  34. 8.6.3 Melior Discovery In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Melior Discovery In Vivo Pharmacology Model Product Portfolio
  36. 8.6.5 Melior Discovery Recent Developments
  37. 8.7 NUVISAN GmbH
  38. 8.7.1 NUVISAN GmbH Company Information
  39. 8.7.2 NUVISAN GmbH Business Overview
  40. 8.7.3 NUVISAN GmbH In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NUVISAN GmbH In Vivo Pharmacology Model Product Portfolio
  42. 8.7.5 NUVISAN GmbH Recent Developments
  43. 8.8 Porsolt
  44. 8.8.1 Porsolt Company Information
  45. 8.8.2 Porsolt Business Overview
  46. 8.8.3 Porsolt In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Porsolt In Vivo Pharmacology Model Product Portfolio
  48. 8.8.5 Porsolt Recent Developments
  49. 8.9 Sygnature Discovery
  50. 8.9.1 Sygnature Discovery Company Information
  51. 8.9.2 Sygnature Discovery Business Overview
  52. 8.9.3 Sygnature Discovery In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sygnature Discovery In Vivo Pharmacology Model Product Portfolio
  54. 8.9.5 Sygnature Discovery Recent Developments
  55. 8.10 Aurigene Pharmaceutical Services Ltd
  56. 8.10.1 Aurigene Pharmaceutical Services Ltd Company Information
  57. 8.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
  58. 8.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product Portfolio
  60. 8.10.5 Aurigene Pharmaceutical Services Ltd Recent Developments
  61. 8.11 Reaction Biology
  62. 8.11.1 Reaction Biology Company Information
  63. 8.11.2 Reaction Biology Business Overview
  64. 8.11.3 Reaction Biology In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Reaction Biology In Vivo Pharmacology Model Product Portfolio
  66. 8.11.5 Reaction Biology Recent Developments
  67. 8.12 Addexbio
  68. 8.12.1 Addexbio Company Information
  69. 8.12.2 Addexbio Business Overview
  70. 8.12.3 Addexbio In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Addexbio In Vivo Pharmacology Model Product Portfolio
  72. 8.12.5 Addexbio Recent Developments
  73. 8.13 Paraza Pharma, Inc
  74. 8.13.1 Paraza Pharma, Inc Company Information
  75. 8.13.2 Paraza Pharma, Inc Business Overview
  76. 8.13.3 Paraza Pharma, Inc In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Paraza Pharma, Inc In Vivo Pharmacology Model Product Portfolio
  78. 8.13.5 Paraza Pharma, Inc Recent Developments
  79. 8.14 Aragen Life Sciences Ltd
  80. 8.14.1 Aragen Life Sciences Ltd Company Information
  81. 8.14.2 Aragen Life Sciences Ltd Business Overview
  82. 8.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Aragen Life Sciences Ltd In Vivo Pharmacology Model Product Portfolio
  84. 8.14.5 Aragen Life Sciences Ltd Recent Developments
  85. 8.15 Dalriada
  86. 8.15.1 Dalriada Company Information
  87. 8.15.2 Dalriada Business Overview
  88. 8.15.3 Dalriada In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dalriada In Vivo Pharmacology Model Product Portfolio
  90. 8.15.5 Dalriada Recent Developments
  91. 8.16 Biocytogen
  92. 8.16.1 Biocytogen Company Information
  93. 8.16.2 Biocytogen Business Overview
  94. 8.16.3 Biocytogen In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biocytogen In Vivo Pharmacology Model Product Portfolio
  96. 8.16.5 Biocytogen Recent Developments
  97. 8.17 Charles River Laboratories
  98. 8.17.1 Charles River Laboratories Company Information
  99. 8.17.2 Charles River Laboratories Business Overview
  100. 8.17.3 Charles River Laboratories In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Charles River Laboratories In Vivo Pharmacology Model Product Portfolio
  102. 8.17.5 Charles River Laboratories Recent Developments
  103. 8.18 Pharmacelsu
  104. 8.18.1 Pharmacelsu Company Information
  105. 8.18.2 Pharmacelsu Business Overview
  106. 8.18.3 Pharmacelsu In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Pharmacelsu In Vivo Pharmacology Model Product Portfolio
  108. 8.18.5 Pharmacelsu Recent Developments
  109. 8.19 HitGen Inc
  110. 8.19.1 HitGen Inc Company Information
  111. 8.19.2 HitGen Inc Business Overview
  112. 8.19.3 HitGen Inc In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  113. 8.19.4 HitGen Inc In Vivo Pharmacology Model Product Portfolio
  114. 8.19.5 HitGen Inc Recent Developments
  115. 8.20 TCG Lifesciences
  116. 8.20.1 TCG Lifesciences Company Information
  117. 8.20.2 TCG Lifesciences Business Overview
  118. 8.20.3 TCG Lifesciences In Vivo Pharmacology Model Revenue and Gross Margin (2021-2026)
  119. 8.20.4 TCG Lifesciences In Vivo Pharmacology Model Product Portfolio
  120. 8.20.5 TCG Lifesciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst